Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (431-440 of 578) with videos related to

Pageof 58
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian CancerCaroline Kreuzinger, Angelika Geroldinger, Dominiek Smeets, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 22, 2010
No association between FTO or HHEX and endometrial cancer riskMia M Gaudet, Hannah P Yang, Jesus Gonzalez Bosquet, et al.
Cancers|June 2, 2021
Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer PatientsDavid Cibula, Martina Borčinová, Simone Marnitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Gynecologic Oncology|December 25, 2021
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialPhilipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 6, 2022
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcomeJudith Altmann, Radoslav Chekerov, Christina Fotopoulou, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancerDomenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Pageof 58

Showing results (431-440 of 578) with videos related to

Sort By:
Pageof 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian CancerCaroline Kreuzinger, Angelika Geroldinger, Dominiek Smeets, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 22, 2010
No association between FTO or HHEX and endometrial cancer riskMia M Gaudet, Hannah P Yang, Jesus Gonzalez Bosquet, et al.
Cancers|June 2, 2021
Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer PatientsDavid Cibula, Martina Borčinová, Simone Marnitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Gynecologic Oncology|December 25, 2021
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialPhilipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 6, 2022
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcomeJudith Altmann, Radoslav Chekerov, Christina Fotopoulou, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancerDomenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Pageof 58